Hypertension and dyslipidemia treament in stroke

Area of Science:

• Neurology
• Cardiology
• Public Health

Background:

• Stroke is a leading cause of death and disability globally.
• Arterial hypertension is the primary risk factor for stroke.
• Dyslipidemia is a significant risk factor for ischemic stroke.

Purpose of the Study:

• To outline optimal management strategies for arterial hypertension and dyslipidemia to prevent stroke and recurrence.
• To define target blood pressure and LDL-cholesterol goals for post-stroke patients.

Main Methods:

• Review of current guidelines and evidence for hypertension and dyslipidemia management post-stroke.
• Analysis of recommended antihypertensive drug classes (ACE inhibitors, ARBs, calcium channel blockers, indapamide).
• Evaluation of intensive hypolipidemic therapies (statins, ezetimibe, PCSK9 inhibitors) and their impact on recurrent stroke.

Main Results:

• Careful blood pressure reduction is crucial in the acute stroke phase.
• Chronic hypertension management targets at least 140/90 mm Hg.
• Intensive lipid-lowering therapy to LDL-cholesterol < 1.4 mmol/l and a 50% decrease significantly reduces recurrent stroke incidence.

Conclusions:

• Precise management of arterial hypertension and dyslipidemia is essential for stroke prevention and reducing recurrence.
• Combination therapies with specific drug classes are favorable for managing hypertension.
• Aggressive lipid-lowering strategies are proven effective in decreasing the risk of recurrent stroke.